- Home
- NEWTP vs FBIOP Comparison
NEWTP vs FBIOP Comparison
Compare NEWTP & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWTP | FBIOP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 591 | 101 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEWTP | FBIOP |
|---|---|---|
| Price | $24.30 | $14.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 22.9K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.51 | $4.72 |
| 52 Week High | $24.48 | $13.84 |
Technical Indicators
Market Signals| Indicator | NEWTP | FBIOP |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 75.68 |
| Support Level | $23.73 | $6.71 |
| Resistance Level | $24.48 | N/A |
| Average True Range (ATR) | 0.14 | 0.68 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 92.86 | 100.00 |
Price Performance
Historical ComparisonAbout NEWTP NewtekOne Inc. Depositary Shares Non-Cumulative Perpetual Preferred Stock Series B
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.